StockData
Alterity Therapeutics Ltd logo

Alterity Therapeutics Ltd (ATHE) stock

ATHENasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRNAF
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 28, 2026Score 5/30
$1.86−0.09 (-4.85%)

Close on Nov 17, 2026Market cap $33.80MP/E –Yield –

Alterity Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2026 it was A$17.63M, up 22.4% from the year before. Over ten years it grew 6.3% a year on average. The highest annual figure on record is A$18.64M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026A$17.63M+22.4%
FY2025Jun 30, 2025A$14.40M-22.7%
FY2024Jun 30, 2024A$18.64M+41.3%
FY2023Jun 30, 2023A$13.20M-10.5%
FY2022Jun 30, 2022A$14.75M+20.0%
FY2021Jun 30, 2021A$12.28M+21.6%
FY2020Jun 30, 2020A$10.10M-22.2%
FY2019Jun 30, 2019A$12.98M+93.8%
FY2018Jun 30, 2018A$6.70M+17.5%
FY2017Jun 30, 2017A$5.70M-40.5%
FY2016Jun 30, 2016A$9.59M–

More Alterity Therapeutics figures

See a number that looks wrong?